Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma

Dupilumab significantly reduced the requirement for systemic corticosteroids (SCS) in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with CRSwNP and coexisting asthma typically have a higher disease burden and have more difficulty in managing disease. Here, we repor...

Full description

Saved in:
Bibliographic Details
Published in:Journal of asthma and allergy 2024-01, Vol.17, p.1-8
Main Authors: Gurnell, Mark, Radwan, Amr, Bachert, Claus, Lugogo, Njira, Cho, Seong H, Nash, Scott, Zhang, Haixin, Khan, Asif H, Jacob-Nara, Juby A, Rowe, Paul J, Deniz, Yamo
Format: Article
Language:English
Subjects:
Asthma
asthma control
asthma exacerbation
Care and treatment
chronic rhinosinusitis with nasal polyps
Drug approval
liberty sinus-24
liberty sinus-52
Medical research
Medicin och hälsovetenskap
Medicine, Experimental
Pharmaceutical industry
Short Report
systemic corticosteroids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dupilumab significantly reduced the requirement for systemic corticosteroids (SCS) in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with CRSwNP and coexisting asthma typically have a higher disease burden and have more difficulty in managing disease. Here, we report an analysis of asthma outcomes and SCS use in patients with CRSwNP and coexisting asthma. This was a post hoc analysis of the randomized, placebo-controlled SINUS-24 and SINUS-52 studies (NCT02912468/NCT02898454) in patients with severe CRSwNP and coexisting asthma (patient self-reported) from the pooled intention-to-treat population randomized to dupilumab 300 mg every 2 weeks or placebo. On-treatment SCS use was estimated using Kaplan-Meier analysis. Forced expiratory volume in 1 s (FEV ), percent predicted FEV , and the 6-item Asthma Control Questionnaire (ACQ-6) were assessed at baseline and Week 24 (pooled SINUS-24/52) in patients with/without history of asthma exacerbation or prior SCS use. Of 337 patients with coexisting asthma, 88 (26%) required on-treatment SCS use. The requirement for on-treatment SCS use for any reason was significantly lower with dupilumab (20/167 patients; 12%) vs placebo (68/170; 40%); hazard ratio (95% confidence interval) 0.248 (0.150-0.409);  
ISSN:1178-6965
1178-6965
DOI:10.2147/JAA.S420140